Moreover, Wei et al [31] found that BCAR4 promoted the progression via activating EGFR/PI3K/AKT pathway, which indicated that BCAR4 could be an effective new target for glioma patients' treatment. This evidence concerns the gene EGFR and central nervous system cancer.